Cefpodoxime proxetil in upper respiratory tract infections

Related Experiment Video

Updated: Oct 31, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

E Bergogne-Berezin1

  • 1Department of Microbiology, Bichat-Claude Bernard University Hospital, Paris, France.

Drugs
|January 1, 1991
PubMed

Insights

Cefpodoxime proxetil, a potent oral cephalosporin, effectively treats upper respiratory infections by inhibiting key pathogens. Clinical studies show high response rates and bacterial eradication, supporting its use as a first-choice antibacterial.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Cefpodoxime proxetil is a third-generation oral cephalosporin with broad-spectrum activity.
  • It exhibits potent antibacterial effects against Gram-positive and Gram-negative bacteria.
  • The drug demonstrates high stability against beta-lactamases, common resistance enzymes.

Purpose of the Study:

  • To evaluate the efficacy and safety of cefpodoxime proxetil in treating upper respiratory tract infections (URTIs).
  • To assess cefpodoxime proxetil's pharmacokinetic profile in respiratory tissues.
  • To determine its effectiveness against common respiratory pathogens.

Main Methods:

  • Preliminary clinical studies involved 181 patients diagnosed with URTIs.
  • Tissue concentrations in tonsils, lung parenchyma, and bronchial mucosa were measured.
  • Minimum inhibitory concentrations (MICs) for relevant pathogens were compared to achieved drug levels.

Main Results:

  • Cefpodoxime achieved concentrations in respiratory tissues significantly exceeding MICs for common pathogens.
  • Overall clinical response rates were high: 88.4% in URTIs, 90.3% cure in pharyngotonsillitis, and 95% efficacy in acute sinusitis.
  • Bacterial eradication rates ranged from 78% to 96.7%, particularly for Haemophilus influenzae, streptococci, and Moraxella catarrhalis.

Conclusions:

  • Cefpodoxime proxetil demonstrates potent antibacterial activity and favorable tissue penetration for URTIs.
  • High clinical efficacy and bacterial eradication rates support its use.
  • It is recommended as a first-line treatment for various upper respiratory tract infections.

More Related Videos

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes08:23

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes

Published on: March 2, 2020

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in various...
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Urinary Tract Infection I: Introduction01:26

Urinary Tract Infection I: Introduction

Urinary tract infections (UTIs) impact various parts of the urinary system, including the kidneys, ureters, bladder, and urethra. These infections are generally bacterial, with Escherichia coli being the most common causative agent, often originating from the gastrointestinal tract. However, other bacteria, such as Staphylococcus saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis, are also known to cause UTIs. The type, location, and underlying complexity of the UTI guide both...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...